Linagliptin safety profile: A systematic review

被引：10

作者：

Alves Gomes, Gabrielle Kefrem ^{[1
,2
]}

de Camargos Ramos, Aline Istefane ^{[1
,2
]}

de Sousa, Camila Tavares ^{[1
,2
]}

Sanches, Cristina ^{[1
,2
]}

Pereira, Mariana Linhares ^{[1
,2
]}

Baldoni, Andre Oliveira ^{[1
,2
]}

机构：

[1] Univ Fed Sao Joao del Rei, Campus Ctr Oeste Dona Lindu, BR-35501296 Divinopolis, MG, Brazil

[2] Univ Fed Sao Joao del Rei, CNPq, GPEANTS, Sao Joao del Rei, Brazil

来源：

PRIMARY CARE DIABETES | 2018年 / 12卷 / 06期

关键词：

Dipeptidyl peptidase 4 (DPP-4) inhibitors; Gliptins; Pharmacovigilance; Incretins; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; LONG-TERM SAFETY; DOUBLE-BLIND; INITIAL COMBINATION; JAPANESE PATIENTS; GLYCEMIC CONTROL; PARALLEL-GROUP; TYPE-2; METFORMIN; MONOTHERAPY;

D O I：

10.1016/j.pcd.2018.04.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: To describe the safety profile of linagliptin. Methodology: Systematic review using PubMed/MEDLINE, BVS and Web of Science. The search strategy "Linagliptin" AND "safety" was used. The inclusion criteria were clinical trials with a control group composed of conventional DM2 pharmacotherapy. Results: We identified 16 studies, and the most frequent adverse events (AEs) were nasopharyngitis with linagliptin at 5 and 10 mg in monotherapy (31.6% and 29.6%, respectively) and gastrointestinal events (>10.0%) with linagliptin in combination. Of the AEs, 14.9 (+/- 3.1)% were associated with the use of linagliptin in monotherapy, and 17.6 (+/- 6.0)% in combination. The linagliptin AEs have a varied occurrence and frequency, ranging from mild to moderate intensity. (C) 2018 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.

引用

页码：477 / 490

页数：14

共 43 条

[1] Hypoglycaemia in Type 2 diabetes [J].